<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275169</url>
  </required_header>
  <id_info>
    <org_study_id>ASLBari</org_study_id>
    <nct_id>NCT02275169</nct_id>
  </id_info>
  <brief_title>FSH Treatment for Non-obstructive Azoospermic Patients</brief_title>
  <official_title>Follicle-stimulating Hormone Treatment for Infertile Male Patients With Non-obstructive Azoospermia: a Multicenter Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Sanitaria Locale Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Sanitaria Locale Bari</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to evaluate the effect of highly purified human follicle-stimulating
      hormone treatment on the chance of retrieving testicular sperm (sperm retrieval rate) from
      infertile male patients with non-obstructive azoospermia of unknown origin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary reports showed that hormonal treatment may improve the chance of retrieving
      viable testicular sperm from men with NOA, but no RCT are available in the field. This
      randomized placebo-controlled clinical trial sought to evaluate whether the testicular sperm
      retrieval rate could result higher in NOA patients treated with follicle-stimulating hormone
      compared to placebo-treated NOA subjects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sperm retrieval rate (SRR)</measure>
    <time_frame>three months</time_frame>
    <description>testicular sperm retrieval rate after three months of urofollitropin treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IVF pregnancy rate</measure>
    <time_frame>three to six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVF implantation rate</measure>
    <time_frame>three to six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Azoospermia</condition>
  <arm_group>
    <arm_group_label>Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urofollitropin 150 IU ampoules three times a week for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ampoules three times a week for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urofollitropin</intervention_name>
    <description>Urofollitropin 75 IU 2 ampoules three times a week for three months</description>
    <arm_group_label>Treated</arm_group_label>
    <other_name>Fostimon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo ampoules administered three times a week for three months</description>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Azoospermia;

          -  testis longitudinal axis less than 4.5 cm;

          -  serum follicle-stimulating hormone greater than 7.6 IU/L

        Exclusion Criteria:

          -  History of testicular biopsy,

          -  malignancy,

          -  varicocele,

          -  hyperprolactinemia,

          -  thyroid disfunction,

          -  chemotherapy,

          -  radiotherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ettore Caroppo, MD</last_name>
    <role>Study Director</role>
    <affiliation>ASL Bari</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Niederberger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University at Illinois at Chicago UIC College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alayman Hussein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>El Minia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ettore Caroppo, MD</last_name>
    <phone>+393479103660</phone>
    <email>ecaroppo@teseo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Craig Niederberger, MD</last_name>
    <phone>3129969330</phone>
    <email>craignied@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Sussman EM, Chudnovsky A, Niederberger CS. Hormonal evaluation of the infertile male: has it evolved? Urol Clin North Am. 2008 May;35(2):147-55, vii. doi: 10.1016/j.ucl.2008.01.010. Review.</citation>
    <PMID>18423236</PMID>
  </reference>
  <reference>
    <citation>Schoor RA, Elhanbly S, Niederberger CS, Ross LS. The role of testicular biopsy in the modern management of male infertility. J Urol. 2002 Jan;167(1):197-200.</citation>
    <PMID>11743304</PMID>
  </reference>
  <results_reference>
    <citation>Caroppo E, Niederberger C, Vizziello GM, D'Amato G. Recombinant human follicle-stimulating hormone as a pretreatment for idiopathic oligoasthenoteratozoospermic patients undergoing intracytoplasmic sperm injection. Fertil Steril. 2003 Dec;80(6):1398-403.</citation>
    <PMID>14667875</PMID>
  </results_reference>
  <results_reference>
    <citation>Kato Y, Shiraishi K, Matsuyama H. Expression of testicular androgen receptor in non-obstructive azoospermia and its change after hormonal therapy. Andrology. 2014 Sep;2(5):734-40. doi: 10.1111/j.2047-2927.2014.00240.x. Epub 2014 Jun 12.</citation>
    <PMID>24919724</PMID>
  </results_reference>
  <results_reference>
    <citation>Hussein A, Ozgok Y, Ross L, Rao P, Niederberger C. Optimization of spermatogenesis-regulating hormones in patients with non-obstructive azoospermia and its impact on sperm retrieval: a multicentre study. BJU Int. 2013 Mar;111(3 Pt B):E110-4. doi: 10.1111/j.1464-410X.2012.11485.x. Epub 2012 Sep 7.</citation>
    <PMID>22958644</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>January 30, 2015</last_update_submitted>
  <last_update_submitted_qc>January 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Sanitaria Locale Bari</investigator_affiliation>
    <investigator_full_name>Ettore Caroppo</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>follicle stimulating hormone treatment</keyword>
  <keyword>azoospermia nonobstructive</keyword>
  <keyword>male infertility</keyword>
  <keyword>follicle stimulating hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azoospermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

